BACKGROUND: Serum fibroblastic growth factor (FGF) 23 has recently been established as a major physiological regulator of phosphate homeostasis and may have a causal role in adverse cardiovascular and bone outcomes. However its role in states of disordered phosphate homeostasis and normal kidney function is as yet under characterised. AIMS: To investigate whether this biomarker of vascular calcification and adverse bone outcomes is detectable in patients with sarcoidosis. DESIGN: We conducted a cross sectional study on a convenience sample of patients presenting with acute sarcoidosis to a respiratory tertiary referral unit. METHODS: We set out to systematically examine the characteristics and determinants of serum FGF-23 in patients presenting with acute sarcoidosis. RESULTS: We studied 39 patients, 26 were male. Mean (SD) age was 33 (9.6) years. 15.4% of patients had a serum level of FGF-23 ≥ 9.9 pg/mL. The remaining 84.6% of patients had a serum FGF-23 < 9.9 pg/mL. Those with a detectable serum FGF-23 had a significantly higher serum calcium (P = 0.007), and lower serum iPTH (P<0.001). Serum phosphate and 25-hydroxyvitamin D were not statistically significantly different between groups (P=0.25 and P=0.83). The proportion of patients with stage II disease on CXR was higher in those with a detectable FGF-23 (P<0.001). CONCLUSIONS: Serum FGF-23 was below the level of detection in the majority of this cohort of patients presenting with acute sarcoidosis. A detectable serum FGF-23 was associated with a higher serum calcium and lower serum iPTH.
BACKGROUND: Serum fibroblastic growth factor (FGF) 23 has recently been established as a major physiological regulator of phosphate homeostasis and may have a causal role in adverse cardiovascular and bone outcomes. However its role in states of disordered phosphate homeostasis and normal kidney function is as yet under characterised. AIMS: To investigate whether this biomarker of vascular calcification and adverse bone outcomes is detectable in patients with sarcoidosis. DESIGN: We conducted a cross sectional study on a convenience sample of patients presenting with acute sarcoidosis to a respiratory tertiary referral unit. METHODS: We set out to systematically examine the characteristics and determinants of serum FGF-23 in patients presenting with acute sarcoidosis. RESULTS: We studied 39 patients, 26 were male. Mean (SD) age was 33 (9.6) years. 15.4% of patients had a serum level of FGF-23 ≥ 9.9 pg/mL. The remaining 84.6% of patients had a serum FGF-23 < 9.9 pg/mL. Those with a detectable serum FGF-23 had a significantly higher serum calcium (P = 0.007), and lower serum iPTH (P<0.001). Serum phosphate and 25-hydroxyvitamin D were not statistically significantly different between groups (P=0.25 and P=0.83). The proportion of patients with stage II disease on CXR was higher in those with a detectable FGF-23 (P<0.001). CONCLUSIONS: Serum FGF-23 was below the level of detection in the majority of this cohort of patients presenting with acute sarcoidosis. A detectable serum FGF-23 was associated with a higher serum calcium and lower serum iPTH.
Authors: Mehdi Mirsaeidi; Hesham R Omar; Andrew Calzadilla; Ahmad El Khatib; Philip Whitney; Nadera Sweiss; Daniel Culver; Michael Campos; Robert Baughman; Roberto Machado Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2018-04-28 Impact factor: 0.670
Authors: Elliott D Crouser; Lisa A Maier; Kevin C Wilson; Catherine A Bonham; Adam S Morgenthau; Karen C Patterson; Eric Abston; Richard C Bernstein; Ron Blankstein; Edward S Chen; Daniel A Culver; Wonder Drake; Marjolein Drent; Alicia K Gerke; Michael Ghobrial; Praveen Govender; Nabeel Hamzeh; W Ennis James; Marc A Judson; Liz Kellermeyer; Shandra Knight; Laura L Koth; Venerino Poletti; Subha V Raman; Melissa H Tukey; Gloria E Westney; Robert P Baughman Journal: Am J Respir Crit Care Med Date: 2020-04-15 Impact factor: 21.405
Authors: Paolo Cameli; Carla Caffarelli; Rosa Metella Refini; Laura Bergantini; Miriana d'Alessandro; Martina Armati; Maria Dea Tomai Pitinca; Piersante Sestini; Stefano Gonnelli; Elena Bargagli Journal: Front Med (Lausanne) Date: 2020-10-29